Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer

Summary of Deaths During Study

Time frame: baseline through last cycle on study drug (eight 21-day cycles)

Progression Free Survival (PFS)

PFS was defined as the date of enrollment to the first date of documented disease progression or death from any cause. Because the median was not reached, results are presented as the Outcome: Number of Participants with Disease Progression or Death at Various Timepoints.

Time frame: baseline to measured progressive disease or death from any cause (up to 68 months)

Overall Survival

Overall survival was defined as the date of enrollment to the date of death from any cause. Because the median was not reached, results will be presented as the Outcome: Number of Participants who Died from Any Cause at Various Timepoints.

Time frame: baseline to date of death from any cause up to 68 months

Time to Treatment Failure

Time to treatment failure was defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed. Because the upper limit of the 95% Confidence Interval of median survival was not calculable, results are presented as the Outcome: Number of Participants with Time to Treatment Failure at Various Timepoints.